Can an educational podcast improve the ability of parents of primary school children to assess the reliability of claims made about the benefits and harms of treatments: study protocol for a randomised controlled trial

Daniel Semakula 1,3*, Allen Nsangi 1,3, Matt Oxman 2, Astrid Austvoll-Dahlgren 2, Sarah Rosenbaum 2, Margaret Kaseje 4, Laetitia Nyirazinyoye 5, Atle Fretheim 2,3, Iain Chalmers 6, Andrew D. Oxman 2 and Nelson K. Sewankambo 1

Abstract

Background: Claims made about the effects of treatments are very common in the media and in the population more generally. The ability of individuals to understand and assess such claims can affect their decisions and health outcomes. Many people in both low- and high-income countries have inadequate aptitude to assess information about the effects of treatments. As part of the Informed Healthcare Choices project, we have prepared a series of podcast episodes to help improve people’s ability to assess claims made about treatment effects. We will evaluate the effect of the Informed Healthcare Choices podcast on people’s ability to assess claims made about the benefits and harms of treatments. Our study population will be parents of primary school children in schools with limited educational and financial resources in Uganda.

Methods: This will be a two-arm, parallel-group, individual-randomised trial. We will randomly allocate consenting participants who meet the inclusion criteria for the trial to either listen to nine episodes of the Informed Healthcare Choices podcast (intervention) or to listen to nine typical public service announcements about health issues (control). Each podcast includes a story about a treatment claim, a message about one key concept that we believe is important for people to be able to understand to assess treatment claims, an explanation of how that concept applies to the claim, and a second example illustrating the concept.

We designed the Claim Evaluation Tools to measure people’s ability to apply key concepts related to assessing claims made about the effects of treatments and making informed health care choices. The Claim Evaluation Tools that we will use include multiple-choice questions addressing each of the nine concepts covered by the podcast. Using the Claim Evaluation Tools, we will measure two primary outcomes: (1) the proportion that ‘pass’, based on an absolute standard and (2) the average score. (Continued on next page)
Background

The ability of individuals to obtain, process, and understand basic health information is a crucial element in making health care choices [1]. Such ability is often limited in both low- and high-income countries [2, 3]. Studies have revealed limited ability among patients, their caregivers and the public to assess the benefits and safety of treatments, and poor understanding of informed consent [4, 5], random allocation [6], risks [7, 8], and drug approval [9]. Some studies have found surprisingly low levels of knowledge of evidence-based medicine principles among health workers [10–12].

A poor understanding of health care evidence, and inadequate ability to recognise claims made about the effects of health care, can increase or diminish the willingness of individuals to seek care or participate in research. It may raise expectations (sometimes falsely), may dash hopes, or may provoke alarm (sometimes unnecessarily). It can result in low uptake of effective interventions, and inappropriate utilisation of health services [13]. It can also create communication barriers between health workers and patients [14, 15] and increase the costs of care [16, 17]. Despite these problems, there is only a handful of open-access tools to educate people to appraise information about the benefits and safety of treatments [18–22], or tools that simplify the interpretation of research information [23, 24]. To fill this gap, we have developed the Informed Healthcare Choices (IHC) resources which we are currently evaluating.

Improving access to reliable health information in the mass media – such as the Internet, radio, TV and print media – has the potential to affect individual health behaviours, health care utilisation, health care practices, and health policy [25, 26]. However, there are substantial barriers that prevent journalists from improving the scientific quality of their reports [27], and evaluations of health stories in the media have consistently found major shortcomings [28–30]. Therefore, users, listeners, viewers, and readers must be able to appraise the trustworthiness of claims made about the effects of treatments.

We have identified 32 key concepts that are relevant to evidence-informed decision-making that people need to understand and apply to assess the trustworthiness of claims made about treatment effects [31]. These concepts are grouped into six domains:

1. Recognising the need for fair comparisons of treatments
2. Judging whether a comparison of treatments is a fair comparison
3. Understanding the role of chance
4. Considering all the relevant fair comparisons
5. Understanding the results of fair comparisons of treatments
6. Judging whether fair comparisons of treatments are relevant

We have developed an educational podcast (a series of audio messages) to teach people how to apply nine of the 32 concepts in judging claims made about the effects of treatments. We settled for the nine concepts after a series of user-tests in which we identified some concepts as being more relevant than others for our target audience and easier than others for people to understand [32]. If resources allow, we plan to develop messages for other concepts, taking account of the lessons learned from this trial. The purpose of this randomised trial is, therefore, to evaluate the effects of this podcast on listeners’ abilities to assess claims made about the effectiveness and safety of treatments. We refer to this podcast as the Informed Healthcare Choices (IHC) podcast.

Objectives

Primary objective

To evaluate the effects of the IHC podcast on the ability of parents of primary school children to assess claims made about the effects of treatments.

Secondary objectives

1. To evaluate the effects of the IHC podcast on listeners’ knowledge, attitudes, and intended
behaviours regarding assessing claims and making decisions
2. To compare participants’ self-assessed ability to assess the reliability of claims made about treatment effects and their objective ability as measured by the Claim Evaluation Tools
3. To evaluate the effects of the IHC podcast 1-year post intervention

Methods
Study design
This will be a two-arm, parallel-group, individual-randomised trial evaluating the impacts of a podcast series designed to teach concepts of evidence-informed decision-making to parents of primary school children in Uganda (Fig. 1).

Setting
The study will be conducted in central Uganda within the communities in which participants live and work. Uganda is a landlocked country in East-Central Africa. It is a multiethnic country with slightly over 70% of the population aged below 25 years. The country has a life expectancy at birth of 54.9 years, total fertility rate of 5.9 children, literacy rate of 78.4%, maternal mortality ratio of 343 per 100,000 live births, and infant mortality rate of 59 per 1000 live births. It has 0.1 physicians per 1000 people [33].

Study population and random allocation
Our study population will be parents of primary school children in schools with limited educational and financial resources. We will draw a sample of parents of children from schools participating in a cluster-randomised trial of IHC primary school resources, designed to help primary school children understand and assess claims made about treatment effects [34].

All public and private primary schools in the central region of Uganda will be eligible to participate in the IHC primary school resources trial. The only exclusions will be international schools, special needs children’s schools for the deaf and blind, and schools or classes that participated in the user-testing and piloting of the teaching resources. We intend to include at least 120 schools in that trial.

Inclusion and exclusion criteria
Inclusion
- Parents of children attending the schools participating in the trial of the IHC teaching resources
- The ability to communicate in the language of the podcast (English or Luganda)
- Consent to participate in the study

Exclusion
- Being unable to hear
- Not contactable by phone
- Health researchers
- Parents who have participated in the development and user-testing of the podcast
- Parents of children who participated in the development and user-testing of the children’s resources [34]

Sampling technique
We will randomly select at least 30 schools among the 120 participating in the related trial evaluating the effectiveness of IHC materials designed for primary school children [34]. This number is informed by findings from our earlier engagements with parents, in which only about 10 to 20 parents attended meetings that are not on the usual school programme. About half of the schools selected will be from the intervention arm and the other half from the control arm of the schools participating in the trial evaluating primary school resources. In each of the selected schools we will
create a list of parents of P.5 children and invite them to a meeting at the schools. At these meetings we will provide parents with information about the podcast trial and seek their consent to participate.

Because parents who attend meetings might be different than those who do not, we will also make an effort to reach parents who will not have attended the meetings through phone calls, where possible.

Parents who accept to participate will be asked to sign a Consent Form (Additional files 1 and 2) before randomisation to begin their participation in the study.

We will provide information about the trial to participants in a brochure designed as part of a package inviting parents to participate. This information will also be available on the participants’ Informed Consent Forms and will be written in the two most commonly spoken languages (English and Luganda).

Random allocation

Methods for stratification and randomisation

We will stratify our sample proportionately by the highest level of education attained (primary school and below, secondary school, or tertiary education) and whether their children are in a school that is in the intervention or control arm of the IHC primary school resources trial.

We will use computer-generated blocked randomisation. A statistician or other senior researcher at the clinical trials unit at the College of Health Sciences, Makerere University who is not a member of the IHC research team will generate the allocation sequences for the two comparison groups. A web-based random number generator at www.sealedenvelope.com will be used to obtain random permuted blocks with varying block sizes of 4 and 6, and equal allocation ratios, both within blocks and within strata, as shown in Table 1 below.

As shown in Table 1 above, the list will have study codes that are unique for each participant (column 7), against which we will attach an ordered array of numbers (column 6) spanning the full breadth of our sample size within each stratum. Each study code will be printed on a separate opaque envelope.

Methods for allocation concealment

The allocation group corresponding to each study code will be printed on a separate slip, inserted and sealed in the corresponding opaque envelope. As shown in the list above, the first participant to be recruited among those with primary or no education will have the study code YL9 on their envelope, inside of which will be a small note with their allocation group (group A).

To reduce the risk of bias during allocation a separate list containing the study participant number, and corresponding study code and number within each stratum, will be generated for each of the three education-level strata (up to and including primary, at least secondary and tertiary), as shown in Table 2 below. This list – which will not identify the study arm – will be given by the statistician to a research assistant who will be in charge of group allocation.

Upon completion of procedures for confirming consent of a willing participant the research assistant responsible for recruiting the participant will call the research assistant in charge of group allocation. The research assistant responsible for allocation will then open the next available envelope in the stratum, corresponding to the participant’s education level and study arm of the child’s school, to determine the study group to which the parent will be allocated.

The interventions

Participants in the intervention group will listen to a series of podcast episodes designed to teach people to assess

---

**Table 1** Excerpt from a sample randomisation list

| Block | Block | Study | Education | Study | Study |
|-------|-------|-------|-----------|-------|-------|
| 1     | 4     | Group A | ≤ primary | 1     | YL9   |
| 1     | 4     | Group A | ≤ primary | 2     | PX5   |
| 1     | 4     | Group B | ≤ primary | 3     | JP3   |
| 1     | 4     | Group B | ≤ primary | 4     | OB2   |
| 2     | 4     | Group A | ≤ primary | 5     | XD6   |
| 2     | 4     | Group A | ≤ primary | 6     | JD0   |
| 2     | 4     | Group B | ≤ primary | 7     | NU5   |
| 2     | 4     | Group B | ≤ primary | 8     | SS0   |
| 3     | 4     | Group B | ≤ primary | 9     | SK0   |
| 3     | 4     | Group A | ≤ primary | 10    | QN4   |

*List generated from www.sealedenvelope.com

**Table 2** Sample participant recruitment lists for each stratum

| Stratum 1: Primary school and below | Stratum 2: At least secondary school | Stratum 3: At least tertiary education |
|-------------------------------------|-------------------------------------|-------------------------------------|
| Number within stratum | Study code | Number within stratum | Study code | Number within stratum | Study code |
| 1 | YL9 | 1 | FO4 | 1 | TH4 |
| 2 | PX5 | 2 | HG6 | 2 | UW0 |
| 3 | JP3 | 3 | GS3 | 3 | AT5 |
| 4 | OB2 | 4 | PS9 | 4 | SX4 |
| 5 | XD6 | 5 | YE9 | 5 | UJ7 |
| 6 | JD0 | 6 | BH7 | 6 | XD9 |
| 7 | NU5 | 7 | HN6 | 7 | RJ7 |
| 8 | SS0 | 8 | TY7 | 8 | CS1 |
| 9 | SK0 | 9 | DT3 | 9 | BC4 |
| 10 | QN4 | 10 | FZ1 | 10 | ED1 |
claims made about treatment effects (the IHC podcast). Each episode includes a short story with an example of a treatment claim, a simple explanation of a concept used to assess that claim, another example of a claim illustrating the same concept, and its corresponding explanation. In each story there is a question about the trustworthiness of a claim, which is resolved by applying the relevant key concept. All episodes have a conclusion with a take-home message emphasising the concept of evidence-informed, health decision-making. The examples used in the podcast are for claims made about treatments for health conditions, which are of interest to the target audience, such as malaria, diarrhoea, and HIV/AIDS. We have also included claims made about some common practices, such as contraception, which are of interest to our audience.

The topics and claims were identified from scanning recent mass media reports and interviewing parents [32]. There are eight main episodes in the series covering the nine core concepts (Table 3). Each episode lasts about 5 min. One of the episodes (episode 1) covers two closely related key concepts (1.1 and 5.1 in Table 3). Two additional episodes introduce the podcast and summarise the key messages from the first eight episodes, respectively. The podcast also has a song (the IHC theme song), sections of which play at the beginning, in the background and at the end of the episodes. The lyrics of the song were designed to reinforce the messages of the podcast and focus on being careful about claims, and the important questions to ask when we hear claims made about treatment effects. The final structure, content, presentation of the content in each episode, and the series as a whole was informed by an iterative user-centred process of development and user-testing described in another paper [32]. This process involved consultation with various stakeholders, including parents in our target audience, on the appropriate content to be included, and the presentation of this content in each episode, and in the podcast as a whole [32]. The numbering in the first column in the table below relates to numbering of the key concepts in their respective domains, as presented by Austvoll-Dahlgren et al. [31].

A summary of the concepts contained in each episode of the podcast is shown in Table 4 below.

Participants in the control group will receive typical public service announcements about conditions of interest to our target audience, including malaria, HIV/AIDS, and diarrhoea, that have been included in the podcast. These audio messages are already being aired or have in the recent past been aired on radio. They are freely available and will be sourced from radio stations and media houses involved in disseminating information from the Ministry of Health.

**Delivery of the interventions**

The interventions will be delivered over a period of 7 to 10 weeks to participants in the communities where they live or work. At least 20 research assistants will help in the field recruitment, administration of the intervention, follow-up of participants in the community, and administration of the outcome assessment tool. Each research assistant will be allocated about 25 participants to follow up through the duration of the study. The research assistants will visit all their allocated participants every week, delivering the interventions on portable media players to an average of four participants per day. In this study setting this approach is currently the most practical and most reliable way of delivering the interventions for this trial.

One-time brief interventions have not been shown to improve knowledge of evidence-based medicine principles [35, 36] among health workers. So, as part of our intervention, at every visit we will play a recap of the previous episodes before playing the new episodes. Each participant will receive at least one supervised listening session of every episode, delivered by the research assistants over 7 to 10 weeks. In addition to the messages delivered by the research assistants, we will provide participants with the complete podcast on MP3 players, so that they can replay the episodes at their convenience. For the intervention group we will start with simpler concepts and gradually introduce more difficult concepts as the podcast series progresses, as summarised in Table 5 below. For the control group we will introduce episodes with health conditions that are similar to those being delivered in the intervention group at a defined period of time. The timing of study procedures is summarised in Fig. 2 below.

**Outcome assessment**

We will use a modified version of the Claim Evaluation Tools as the outcome measure [37]. The Claim Evaluation Tools consist of multiple-choice questions that assess an individual’s ability to apply 32 concepts that people need to be able to understand and apply to assess the validity of treatment claims and to make informed health care choices. In addition, it includes questions that assess intended behaviours, self-efficacy, attitudes, and satisfaction. Development of the Claim Evaluation Tools has been based on extensive qualitative and quantitative feedback from methodological experts, health professionals, teachers, and members of the public. We have conducted psychometric testing and Rasch analysis with a diverse sample of 1000 people, including P.5 children exposed to pilot versions of the IHC primary school resources, children who were not exposed, adults with little or no exposure to the concepts, and adults who are familiar with the concepts. The evaluation tool was found to have high reliability (Cronbach’s alpha 0.81), and to be unidimensional (there was no evidence of subdimensions measuring different traits). Furthermore, there was weak or no dependence between items (no items were redundant). Results from the pilot revealed
### Table 3 The nine concepts included in the IHC podcast

| Concepts                                                                 | Explanations                                                                                                                                                                                                 | Implications                                                                                                             |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| 1.1 Treatments may be harmful                                            | People often exaggerate the benefits of treatments and ignore or downplay potential harms. However, few effective treatments are 100% safe.                                                                 | Always consider the possibility that a treatment may have harmful effects                                                |
| 1.2 Personal experiences or anecdotes (stories) are an unreliable basis for assessing the effects of most treatments | People often believe that improvements in a health problem (e.g., recovery from a disease) were due to having received a treatment. Similarly, they might believe that an undesirable health outcome was due to having received a treatment. However, the fact that an individual got better after receiving a treatment does not mean that the treatment caused the improvement, or that others receiving the same treatment will also improve. The improvement (or undesirable health outcome) might have occurred even without treatment. | Claims made about the effects of a treatment may be misleading if they are based on stories about how a treatment helped individual people, or if those stories attribute improvements to treatments that have not been assessed in systematic reviews of fair comparisons |
| 1.3 A treatment outcome may be associated with a treatment, but not caused by the treatment | The fact that a treatment outcome (i.e., a potential benefit or harm) is associated with a treatment does not mean that the treatment caused the outcome. For example, people who seek and receive a treatment may be healthier and have better living conditions than those who do not seek and receive the treatment. Therefore, people receiving the treatment might appear to benefit from the treatment, but the difference in outcomes could be because of their being healthier and having better living conditions, rather than because of the treatment. | Unless other reasons for an association between an outcome and a treatment have been ruled out by a fair comparison, do not assume that the outcome was caused by the treatment |
| 1.4 Widely used treatments or treatments that have been used for a long time are not necessarily beneficial or safe | Treatments that have not been properly evaluated but are widely used or have been used for a long time are often assumed to work. Sometimes, however, they may be unsafe or of doubtful benefit. | Do not assume that treatments are beneficial or safe simply because they are widely used or have been used for a long time, unless this has been shown in systematic reviews of fair comparisons of treatments |
| 1.6 Opinions of experts or authorities do not always provide a reliable basis for deciding on the benefits and harms of treatments | Physicians, researchers, patient organisations, and other authorities often disagree about the effects of treatments. This may be because their opinions are not always based on systematic reviews of fair comparisons of treatments. | Do not rely on the opinions of experts or other authorities about the effects of treatments, unless they clearly base their opinions on the findings of systematic reviews of fair comparisons of treatments |
| 2.1 Evaluating the effects of treatments requires appropriate comparisons | If a treatment is not compared to something else, it is not possible to know what would happen without the treatment, so it is difficult to attribute outcomes to the treatment. | Always ask what the comparisons are when considering claims made about the effects of treatments. Claims that are not based on appropriate comparisons are not reliable |
| 2.2 Apart from the treatments being compared, the comparison groups need to be similar (i.e., ‘like needs to be compared with like’) | If people in the treatment comparison groups differ in ways other than the treatments being compared, the apparent effects of the treatments might reflect those differences rather than actual treatment effects. Differences in the characteristics of the people in the comparison groups might result in estimates of treatment effects that appear either larger or smaller than they actually are. A method, such as allocating people to different treatments by assigning them random numbers (the equivalent of flipping a coin), is the best way to ensure that the groups being compared are similar in terms of both measured and unmeasured characteristics. | Be cautious about relying on the results of nonrandomised treatment comparisons (for example, if the people being compared chose which treatment they received). Be particularly cautious when you cannot be confident that the characteristics of the comparison groups were similar. If people were not randomly allocated to treatment comparison groups, ask if there were important differences between the groups that might have resulted in the estimates of treatment effects appearing either larger or smaller than they actually are. |
| 4.1 The results of single comparisons of treatments can be misleading     | A single comparison of treatments rarely provides conclusive evidence and results are often available from other comparisons of the same treatments. These other comparisons may have different results or may help to provide more reliable and precise estimates of the effects of treatments. | The results of single comparisons of treatments can be misleading. |
that parents in the intervention group performed slightly better compared with those in the control group. Many of the participants in the pilot preferred Luganda to English and had difficulty reading the questions in English.

After removing some questions, we modified the remaining questions that did not perform well according to the Rasch analysis, and revised and simplified the text where needed. The items were also translated into Luganda and adapted for audio administration. In the second psychometric testing, the Claim Evaluation Tools were administrated to a similar sample as described in the first psychometric test, but approximately half of the sample received the items as a written questionnaire in English and the other half received the Luganda audio versions. The results of this test suggested that the items administered in English performed very well according to the Rasch model, and with high reliability. Furthermore, the items were also less difficult than what was found in the first psychometric testing before the revisions. The results also suggested that the Luganda versions of items had evidence of under-discrimination and differential item functioning in seven out of 29 items. These items were revised to improve fit to the Rasch model.

Based on these two psychometric tests, a selection of 18 multiple-choice items addressing the nine concepts that the IHC podcast covers will be used (Additional file 3). Each key concept is evaluated by two items. We chose items with high reliability (fit to the Rasch model) and those with an appropriate difficulty level.

Parents in both arms of the trial will complete the questionnaires after they have listened to the podcast or public service announcements. Research assistants will deliver the questionnaires, ensuring that the parents have adequate time to answer the questions and ensure that the questionnaires have been completed fully.

**Absolute standard (for passing scores)**

We will use an absolute (criterion referenced) standard to set a passing score for the version of the Claim Evaluation Tools that we will use, i.e. based on how much the parents know and are able to apply. Parents will be counted as ‘passing’ or ‘failing’ depending on whether they meet a specified criterion. We used a combination of Nedelsky’s [38] and Angoff’s [39] methods to determine the criterion, which is a cut-off for a passing score, as described in Additional file 4. In addition, we determined a second cut-off for a score that indicates mastery of the nine concepts, using the same methods, as described in Additional file 4. The criterion for passing is a minimum of 11 out of 18 questions answered correctly. The criterion for mastery is a minimum of 15 out of 18 questions answered correctly.

**Primary outcomes**

1. The difference between the intervention and control groups in the proportion of participants with a passing score
2. The mean difference in the score (number of correct answers) for all of the questions that assess their ability to apply the nine concepts that are included in the IHC podcast

**Secondary outcomes**

1. The difference between the intervention and control groups in the proportion of parents with a score indicating mastery of the concepts (see above)
2. The difference between the intervention and control groups for each concept
3. Differences in attitudes and intended behaviours between the two groups

The intervention and control groups will complete the Claim Evaluation Tools after listening to all of the IHC episodes or public service announcements, respectively. We will evaluate the effects of the IHC podcast series again after 1 year, using the same outcome measures. We will try to locate participants who will have moved from their original residence or work place and document those who are lost to follow-up, as well as the reasons, where possible.

**Blinding**

Because of the nature of the intervention, the research assistants who will deliver the intervention, the principle
investigator supervising them, and the participants in the study will not be blinded. The statistician who will analyse the study results will not be told which group is the intervention group until after the analyses are completed.

To ensure uniform performance in delivery of the intervention and assessment of outcomes, all study staff will receive joint training before the start of the trial and will receive refresher training in the course of the trial.

![Table]

| TIMEPOINT** | Enrolment | Randomisation information | Allocation | Post-allocation | Close-out |
|-------------|-----------|---------------------------|------------|-----------------|---------|
| ENROLMENT:  | Week 1    | Week 2                    | Week 3     | Week 4          | Week 5  |
| Eligibility screening | X         |                           |            |                 |         |
| Informed consent | X         |                           |            |                 |         |
| Collection of Bio-data | X         |                           |            |                 |         |
| Allocation | X         |                           |            |                 |         |
| INTERVENTIONS: |           |                           |            |                 |         |
| The IHC* podcast (intervention) |           |                           |            |                 |         |
| Public service announcements (control) |           |                           |            |                 |         |
| Introductory episode | X         |                           |            |                 |         |
| Episodes 1 and 2 | X         |                           |            |                 |         |
| Recaps for episodes 1 and 2 | X         |                           |            |                 |         |
| Episodes 3 and 4 | X         |                           |            |                 |         |
| Recaps for episodes 3 and 4 | X         |                           |            |                 |         |
| Episodes 5 and 6 | X         |                           |            |                 |         |
| Recaps for episodes 5 and 6 | X         |                           |            |                 |         |
| Episodes 7 and 8 | X         |                           |            |                 |         |
| Recap for all episodes (Episode 9) | X         |                           |            |                 |         |
| All Episodes given to participant | X         |                           |            |                 |         |
| ASSESSMENTS: |           |                           |            |                 |         |
| Participants with a passing score on the CLAIM Questionnaire: immediate post-intervention |                   |                           |            | X                 |         |
| Participants with a passing score on the CLAIM Questionnaire: a year after |                   |                           |            | X                 |         |

**Fig. 2 Schedule of enrolment, interventions, and assessments**
We will have standard operating procedures to guide interactions with participants.

**Data collection and management**

**Postrecruitment retention strategies**

We will maintain a database of participants’ contact details and maps to their homes to enable follow-up. The research assistants will keep a study logbook and use a progress tracking checklist (Tables 6 and 7) to keep track of their progress and note any problems with follow-up of participants. We will discuss these problems and ways of addressing them and preventing loss to follow-up at weekly meetings.

**Data collection and management**

We will use paper questionnaires for the outcome assessment and we will collect baseline sociodemographic characteristics using a paper form. For participants who prefer listening to the Luganda version of the podcast but are unable to read Luganda we will use an interviewer-administered, standardised Luganda audio version of the evaluation tool. A research assistant will enter their responses to the audio evaluation tool on a paper questionnaire. To reduce any wrong entries and missing values the research assistants will check the questionnaires for completeness and for unclear responses immediately after completion. We will use Epidata version 3 software [40] to enter all data from the paper questionnaires and convert them into an electronic dataset. To reduce errors during data entry we will double-enter all the data. All data entrants will be trained on the meaning of variables and how they should be entered into the database. Questions that remain unanswered will be scored as ‘wrong’. The lead investigator will double-check the entries.

All copies of Consent Forms will be kept separate from the completed questionnaires and baseline characteristics of the participants. Both signed Informed Consent Forms and completed questionnaires will be kept under lock and key. All electronic data will be password-protected and kept on a separate hard disc, which will be backed up every week to prevent data loss. The hard discs will also be kept under lock and key and access will be restricted to study investigators.

Trial progress reports will be compiled by the study team and submitted to the regulatory bodies (Uganda National Council for Science and Technology and School of Medicine Research and Ethics Committee (SOMREC), Makerere University College of Health Sciences), in accordance with their respective guidelines. Final project reports (including trial reports) will be compiled by the study staff and submitted to the relevant bodies (Research Ethics Committees (RECs) and funders), as per their requirements.

**Analysis**

We will present participants’ age, sex, and highest level of education attained as frequencies and proportions.

For the primary and secondary outcomes, we will use fixed-effect models with the stratification variable (education) modelled as a fixed effect, using logistic regression for dichotomous outcomes, linear regression for continuous outcomes and Poisson regression for count outcomes. For the questions that assess applied knowledge or understanding, missing values will be counted as ‘wrong’ answers.

We will report the proportion (for dichotomous outcomes), mean and standard deviation (for continuous outcomes), or median and interquartile range (for count outcomes) in each group, the estimated difference, the estimated confidence interval for the difference, and the \( P \) value for the difference between groups from the statistical model for each of the primary and secondary outcomes. For attitudes and intended behaviours (Additional file 3), we will dichotomise each outcome by combining, for example, ‘very unlikely’ with ‘unlikely’ and as ‘likely’ with ‘very likely’; and we will report the proportion in each of the four categories.

**Subgroup and exploratory analyses**

Education might affect people’s ability to understand and apply the concepts and to answer questions in the Claim Evaluation Tools. We will explore whether there are differences in the effects of the intervention for participants with primary school education versus secondary school education versus tertiary education. We will conduct tests for interaction for the primary outcomes, and we will use published guidelines to interpret the results of these subgroup analyses [41], using the models described above.

| Table 6 | Study log for monitoring progress of the intervention for each study participant |
|---------|---------------------------------------------------------------------------------|
| Study number | Date enrolled | Study arm |
| Visit number | Date contacted by phone | Date seen | Date intervention was administered | Observations and comments for study visit |

Semakula et al. Trials (2017) 18:31
The children of all participants will be participating in a parallel trial evaluating the effects of IHC teaching resources, designed to teach P.5 school children concepts that they need to understand and apply to assess treatment claims [34], but only half of them will be receiving the IHC teaching resources. By testing for interaction between IHC teaching resources and the podcast in the statistical models described above we will evaluate whether the combination of the podcast and the IHC teaching resources improves outcomes among parents, compared to the podcast alone.

Sample size
We used the method described by Donner [42] to calculate the sample size, based on calculation of odds ratios. The smallest difference between the intervention and control groups that we want to be able to detect in the proportion of respondents with a passing score is 10 percentage points. Assuming that 10% of the control group will achieve a passing score (a conservative estimate, based on data from the pilot [32]), power of 0.90, a two-sided \( P \) value of 0.05, we estimate that 397 participants will be needed to be able to detect an improvement of 10% in the intervention group. Studies of the effects of drug fact boxes and a primer to help people understand risk suggest that this is likely to be an adequate sample size [25, 26]. Allowing for a 20% loss to follow-up gives us a sample size of 497 participants. More specific information about the trial and this protocol is summarised in the SPIRIT checklist (Additional file 5).

Safety monitoring and adverse events
The National Council of Science and Technology in Uganda has given this study a very low rating for risk to participants. Nonetheless, we will monitor unexpected adverse events and problems that might arise.

Stakeholder involvement
We have engaged health researchers, journalists, other media and communications practitioners, teachers, and the general public in developing, revising, piloting, and user-testing the podcast [32].

Reporting, dissemination and notification of results
Authorship of publications arising from this study will be according to contribution. Publications and the resources will be open access, allowing free noncommercial use, distribution, reproduction and further development of the work provided the source is properly cited. We will acknowledge all staff participating in the trial.

The results of this trial will be publicised through a variety of channels. All of the resources will be made available on the IHC project and Testing Treatments interactive websites, and through the Critical Appraisal Resource Library (CARL). They will be disseminated internationally by the IHC project team and through members of our international advisory group, the Cochrane Collaboration (www.cochrane.org), the Evidence-informed Policy Network (www.evipnet.org), the WHO, the Campbell Collaboration (www.campbellcollaboration.org), and other relevant networks and organisations.

Discussion
To the best of our knowledge this is the first randomised trial to assess the use of mass media to promote understanding of the key concepts that are essential to improving people’s ability to critically assess claims made about the effects of treatments. A basic understanding of these concepts is envisaged to improve critical assessment of things that people say about what effects treatments might have if, or when, we use them.

In this context the factors, which may facilitate or hinder people’s understanding of information on assessing claims made about treatment effects, are largely unknown. Therefore, we plan to conduct a process evaluation to explore these and any other issues that might explain why the intervention worked or did not work as expected. We shall use this information to improve the design and administration of future interventions of this nature.

It is expected that recruitment of parents will be slow and follow-up may be difficult. From earlier pilots done in this context, very few parents attended parents’ meetings at schools and those who did arrived very late. The majority of our study participants are very likely to be women since mothers tend to be the ones who commonly attend parents’ meetings. It is not known how representative these will be of our intended study population. In our process evaluation we shall explore reasons why, if this turns out to be the case, and reasons for choosing not to participate among those who decline to consent.
Trial status
This study is currently recruiting participants.

Additional files

- **Additional file 1:** Consent form Podcast trial English version. (DOCX 27 kb)
- **Additional file 2:** Consent form Podcast trial Luganda translated version. (DOCX 29 kb)
- **Additional file 3:** The CLAIM Evaluation Tools. (ZIP 1007 kb)
- **Additional file 4:** Setting a standard for the “Claim 12” and “Claim 9”. (DOCX 28 kb)
- **Additional file 5:** SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*. (DOC 122 kb)

Abbreviations
AIDS: Acquired immunodeficiency syndrome; CARL: Critical Appraisal Resource Library; HIV: Human immunodeficiency virus; IHC: Informed Healthcare Choices; P. 5: Primary five; REC: Research and Ethics Committee; SOMREC: School of Medicine Research and Ethics Committee; UNCST: Uganda National Council for Science and Technology; WHO: World Health Organisation

Acknowledgements
We thank Jan Olggaard-Jensen for help planning the statistical analyses, and all of the many parents, journalists, teachers, and children who helped with the development of the IHC podcast. We would also like to thank the producers and the musicians who helped with the production of IHC theme song and the podcast. Lastly, but not least, we also acknowledge the support extended to us by the research assistants and the members of the National and International Advisory Panels of the IHC project.

Funding
The trial has been funded by the Norwegian Research Council, Project number 220603/H10. The funding body has had no role in the design of the study or in writing reports.

Availability of data and materials
The datasets generated during the study and used in the analyses will be available from the corresponding author on reasonable request.

Authors’ contributions
DS participated in the design of the study, the design of the study interventions, drafting of the study protocol and manuscript, data collection and data management procedures, and is responsible for participant recruitment, data collection and the day-to-day management of the trial. AN participated in the design of the study, the design of the study interventions, drafting of the study protocol and manuscript, data collection and data management procedures, and is responsible for participant recruitment, data collection and the day-to-day management of the trial. ADO conceived the study idea, participated in the design of the study, study interventions, drafting of the study protocol and manuscript, data collection, standards for assessment and data management procedures, and oversees the trial. IC conceived the study idea, participated in the design of the study, study interventions, drafting of the study protocol, data collection, standards for assessment and data management procedures, and oversees the trial. AD participated in the design of the study, the study protocol, data collection and management procedures, and in developing and validating the study evaluation tool. MO and SR had the primary responsibility for preparing the IHC primary school resources. All of the investigators contributed to the development and pilot-testing of the resources. MK participated in the design of the study protocol and the user-testing of the interventions. LN participated in the design of the study protocol and the user-testing of the interventions. AF participated in the design of the study protocol and oversees the implementation of the study. ADO, SR, AA, and IC are principal members of the coordinating group for the trial and, together with NKS and the principal investigators act as the Steering Committee for the trial. They are responsible for final decisions about the protocol and reporting of the results. The principal investigators are responsible for managing data collection. All of the investigators have reviewed the protocol, provided input, and agreed on this version of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study has obtained ethics approval from the Uganda National Council for Science and Technology (UNCST) and the School of Medicine Research and Ethics Committee (SOMREC) at Makerere University College of Health Sciences (REC number 2013-105). Only participants who have provided informed consent (Additional files 1 and 2) will be included in the study. Participants will not be identified by their personal details and all information will be kept confidential.

Trial management
The trial is registered in the Pan African Clinical Trial Registry [43]. Dr. Daniel Semakula is the principal investigator of the trial, assisted by coinvestigator Allen Nsangi. They will be responsible for the practical implementation of the study and its day-to-day management. They will ensure that staff adhere to the protocol and the guidelines for research involving human participants. Dr. Andrew David Oxman, Dr. Atte Fretheim, the IHC Team at the Norwegian Institute of Public Health, and Prof. Nelson K Sewankambo at Makerere University College of Health Sciences will provide oversight and support. The study Sponsor is: Makerere University College of Health Sciences

Contact name: Prof. Nelson K Sewankambo
Address: College of Health Sciences, School of Medicine, Department of Medicine, Level 2, Clinical Research Building, Mulago Hospital and Complex, PO Box 7072 Kampala, Uganda
Phone: 256-414-530021
Email: sewankam@infocom.co.ug

The study sponsor was responsible for the ethical review and approval of the protocol and Nelson K Sewankambo is responsible for overseeing the trial.

The Norwegian Institute of Public Health, recipient of the grant from the Research Council of Norway, is the coordinating centre for the IHC project. The coordinating centre is responsible for financial management of the project, reporting to the funder, and ensuring that the project’s milestones are met.

Author details
1Makerere University College of Health Sciences, New Mulago Hospital Complex, Clinical Research Building, Level 4, PO Box 7072, Kampala, Uganda.
2Norwegian Institute of Public Health, Nydalen, PO Box 4404N-0403 Oslo, Norway.
3University of Oslo, Blindern, Postboks 11300S18 Oslo, Norway.
4Great Lakes University of Kisumu, PO Box 2224-40100, Kisumu, Kenya.
5University of Rwanda, 101, KK 19 Av., University Avenue, PO Box: 5229, Kigali, Rwanda.
6James Lind Initiative, Summertown Pavilion, Middle Way, Oxford OX2 7LG, UK.

Acknowledgements
We thank Jan Olggaard-Jensen for help planning the statistical analyses, and all of the many parents, journalists, teachers, and children who helped with the development of the IHC podcast. We would also like to thank the producers and the musicians who helped with the production of IHC theme song and the podcast. Lastly, but not least, we also acknowledge the support extended to us by the research assistants and the members of the National and International Advisory Panels of the IHC project.

Funding
The trial has been funded by the Norwegian Research Council, Project number 220603/H10. The funding body has had no role in the design of the study or in writing reports.

Availability of data and materials
The datasets generated during the study and used in the analyses will be available from the corresponding author on reasonable request.

Authors’ contributions
DS participated in the design of the study, the design of the study interventions, drafting of the study protocol and manuscript, data collection and data management procedures, and is responsible for participant recruitment, data collection and the day-to-day management of the trial. AN participated in the design of the study, the design of the study interventions, drafting of the study protocol and manuscript, data collection and data management procedures, and is responsible for participant recruitment, data collection and the day-to-day management of the trial. ADO conceived the study idea, participated in the design of the study, study interventions, drafting of the study protocol and manuscript, data collection, standards for assessment and data management procedures, and oversees the trial. IC conceived the study idea, participated in the design of the study, study interventions, drafting of the study protocol, data collection, standards for assessment and data management procedures, and oversees the trial. AD participated in the design of the study, the study protocol, data collection and management procedures, and in developing and validating the study evaluation tool. MO and SR had the primary responsibility for preparing the IHC primary school resources. All of the investigators contributed to the development and pilot-testing of the resources. MK participated in the design of the study protocol and the user-testing of the interventions. LN participated in the design of the study protocol and the user-testing of the interventions. AF participated in the design of the study protocol and oversees the implementation of the study. ADO, SR, AA, and IC are principal members of the coordinating group for the trial and, together with NKS and the principal investigators act as the Steering Committee for the trial. They are responsible for final decisions about the protocol and reporting of the results. The principal investigators are responsible for managing data collection. All of the investigators have reviewed the protocol, provided input, and agreed on this version of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study has obtained ethics approval from the Uganda National Council for Science and Technology (UNCST) and the School of Medicine Research and Ethics Committee (SOMREC) at Makerere University College of Health Sciences (REC number 2013-105). Only participants who have provided informed consent (Additional files 1 and 2) will be included in the study. Participants will not be identified by their personal details and all information will be kept confidential.

Trial management
The trial is registered in the Pan African Clinical Trial Registry [43]. Dr. Daniel Semakula is the principal investigator of the trial, assisted by coinvestigator Allen Nsangi. They will be responsible for the practical implementation of the study and its day-to-day management. They will ensure that staff adhere to the protocol and the guidelines for research involving human participants. Dr. Andrew David Oxman, Dr. Atte Fretheim, the IHC Team at the Norwegian Institute of Public Health, and Prof. Nelson K Sewankambo at Makerere University College of Health Sciences will provide oversight and support. The study Sponsor is: Makerere University College of Health Sciences

Contact name: Prof. Nelson K Sewankambo
Address: College of Health Sciences, School of Medicine, Department of Medicine, Level 2, Clinical Research Building, Mulago Hospital and Complex, PO Box 7072 Kampala, Uganda
Phone: 256-414-530021
Email: sewankam@infocom.co.ug

The study sponsor was responsible for the ethical review and approval of the protocol and Nelson K Sewankambo is responsible for overseeing the trial.

The Norwegian Institute of Public Health, recipient of the grant from the Research Council of Norway, is the coordinating centre for the IHC project. The coordinating centre is responsible for financial management of the project, reporting to the funder, and ensuring that the project’s milestones are met.

Author details
1Makerere University College of Health Sciences, New Mulago Hospital Complex, Clinical Research Building, Level 4, PO Box 7072, Kampala, Uganda.
2Norwegian Institute of Public Health, Nydalen, PO Box 4404N-0403 Oslo, Norway.
3University of Oslo, Blindern, Postboks 11300S18 Oslo, Norway.
4Great Lakes University of Kisumu, PO Box 2224-40100, Kisumu, Kenya.
5University of Rwanda, 101, KK 19 Av., University Avenue, PO Box: 5229, Kigali, Rwanda.
6James Lind Initiative, Summertown Pavilion, Middle Way, Oxford OX2 7LG, UK.

Received: 24 August 2016 Accepted: 23 November 2016
Published online: 21 January 2017

References
1. Institute of Medicine, Committee on Health Literacy. Health literacy: a prescription to end confusion. Washington, DC: National Academy Press; 2004.
2. Morris NS, Grant S, Repp A, Maclean C, Littenberg B. Prevalence of limited health literacy and compensatory strategies used by hospitalized patients. Nurs Res. 2011;60(5):361–6. Epub 1 Sep 2011.
3. Green JA, Mor MK, Shields AM, Sevick MA, Palevsky PM, Fine MJ, et al. Prevalence and demographic and clinical associations of health literacy in patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2011;6(8):1354–60. Epub 10 May 2011.
4. Meneguin S, Zoboli ELCP, Dominguez RZL, Nobre MR, Cesar LAM. Informed consent as viewed by patients participating in cardiology drug trial. Arq Bras Cardiol. 2010;94–9.

5. Manafa O, Lindegger G, Jisselmaiden C. Informed consent in an antiretroviral trial in Nigeria. Indian J Med Ethics. 2007;4(1):26–30. Epub 17 Jul 2008.

6. Robinson E, Kerr C, Stevens A, Lilford R, Braunholtz D, Edwards S, et al. Lay public’s understanding of equipoise and randomisation in randomised controlled trials. Research Support, Non-U.S. Gov't. NHS R&D HTA Programme, 2005 Mar 1366–5278 (Linking) Contract No.: 8.

7. Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment: a randomized trial. Ann Intern Med. 2011;155(287–96. Epub 20 Jul 2011.

8. Woloshin S, Schwartz LM, Welch HG. The effectiveness of a primer to help people understand risk: two randomized trials in distinct populations. Ann Intern Med. 2007;146(4):256–65. Epub 21 Feb 2007.

9. Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med. 2011;171(16):1463–8. Epub 14 Jul 2011.

10. Godwin M, Seguin R. Critical appraisal skills of family physicians in Ontario, Canada. BMC Med Educ. 2003;3(10). http://bmcmededu.biomedcentral.com/articles/10.1186/1472-6920-3-10.

11. Kamalbekova G, Kalieva M. Evidence-based medicine Training: Kazakhstan experience. Int J Risk Saf Med. 2015;27 Suppl 1:95–6.

12. Novak K, Mitt D, Jurin A, et al. Awareness and use of evidence-based medicine databases and Cochrane library among physicians in Croatia. Croat Med J. 2010;51(12):157–64.

13. Berkmann ND, Sheridan SL, Donahue KE, Halpern DC, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155(2):97–107. Epub 20 Jul 2011.

14. Ngoh LN. Health literacy: a barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc. 2009;49(5):e132–46. quiz e47-9. Epub 15 Sep 2009.

15. Easton P, Entwistle VA, Williams B. How the stigma of low literacy can impair patient-professional spoken interactions and affect health: insights from a qualitative investigation. BMC Health Serv Res. 2013;13:319. Epub 21 Aug 2013.

16. Howard DH, Gazmazarian J, Parker RM. The impact of low health literacy on the medical costs of Medicare managed care enrollees. Am J Med. 2005;118(4):371–7.

17. Hawkins AO, Kantayya VS, Sharkey-Asner C. Health literacy: a potential barrier in caring for underserved populations. Dis Mon. 2010;56(12):734–40.

18. Krause L, Schwartz LM, Woloshin S, Oxman AD. Interactive tools to teach the public to be critical consumers of information about health care: what’s out there? Abstract. 19th Cochrane Colloquium, Madrid, Spain, 2008.

19. Hatmi Z, Tavhildari S, Dabiran S, Soheili S, Sabouri Kashani A, Razmahan M. Teaching evidence-based medicine more effectively, Acta Med Iran. 2010;48(5):332–6.

20. Nicholson L, Warde C, Boker J. Faculty training in evidence-based medicine: improving evidence acquisition and critical appraisal. J Contin Educ Health Prof. 2007;27(1):28–33.

21. Muscola A. Guided mentorship in evidence-based medicine for psychiatry: a pilot cohort study supporting a promising method of real-time clinical instruction. Acad Psychiatry. 2008;32(6):475–83.

22. McCluskey A, Lovatini M. Providing education on evidence-based practice improved knowledge but did not change behaviour: a before and after study. BMC Med Educ. 2005;5(40). http://bmcmededuc.biomedcentral.com/articles/10.1186/1472-6920-5-40.

23. Rosenbaum S, Glenton C, Oxman AD. Summary-of-findings tables in Cochrane reviews improved understanding and rapid retrieval of key information. J Clin Epidemiol. 2010;63(6):620–6.

24. Vandvik P, Santesso N, Akl E, You J, Mulla S, Spencer F, et al. Formatting modifications in GRADE evidence profiles improved guideline panelists’ comprehension and accessibility to information. A randomized trial. J Clin Epidemiol. 2012;65(7):748–55.

25. Chapman S, Haynes A, Derrick G, Sturk H, Hall WD, St George A. Reaching ‘an audience that you would never dream of speaking to’: influential public health researchers’ views on the role of news media in influencing policy and public understanding. J Health Commun. 2014;19(2):260–73. Epub 26 Oct 2013.

26. Kostkova P, Fowler D, Wiseman S, Weinberg JR. Major infection events over 5 years: how is media coverage influencing online information needs of health care professionals and the public? J Med Internet Res. 2013;15(7):e107. Epub 17 Jul 2013.

27. Lanson A, Oxman AD, Carling C, Herrin J. Medical messages in the media—barriers and solutions to improving medical journalism. Health Expect. 2003;6(4):323–31. Epub 26 Mar 2004.

28. Lewis M, Orrick P, Myers S. Uncritical reverence in CM reporting: assessing the scientific quality of Australian news media reports. Health Soc Rev. 2010;19(1):57–72.

29. Glenton C, Pausen E, Oxman AD. Portals to Wonderland? Health portals lead confusing information about the effects of health care. BMC Med Inform Decis Mak. 2005;5:7–8.

30. Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, et al. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000;342(22):1645–50.

31. Austvoll-Dahlgren A, Oxman AD, Chalmers I, Naangi A, Glenton C, Lewin S, et al. Key concepts that people need to understand to assess claims about treatment effects. J Evid Based Med. 2015;8(3):112–25. doi:10.1111/jebm.12160.

32. Semakula D, Naangi A, Oxman M, Rosenbaum S, Kaseje M, et al. Development, user-testing and piloting of an educational podcast to improve people’s understanding and ability to assess claims about the effectiveness and safety of treatments (manuscript). 2016.

33. Central Intelligence Agency (CIA). The World Factbook. 2015. Last updated 17 Dec 2015. Available from: https://www.cia.gov/library/publications/resources/the-world-factbook/geos/ug.html. Accessed 11 Jan 2016.

34. Naangi A, Semakula D, Oxman M, Austvoll-Dahlgren A, Rosenbaum S, Kaseje M, et al. Evaluation of resources to teach children in low-income countries to assess the trustworthiness of claims about treatment effects: protocol for a randomised trial. 2016.

35. Ilic D, Tepper K, Missu M. Teaching evidence-based medicine literature searching skills to medical students during the clinical years: a randomized controlled trial. J Med Libr Assoc. 2012;100(3):190–6.

36. El-Khoury M, Thornton R, Chatterji M, Choi SK. Effectiveness of evidence-based medicine databases and Cochrane library among physicians in Croatia. Croat Med J. 2010;51(2):157–64.

37. Austvoll-Dahlgren A, Guttersrud O, Oxman AD, et al. Measuring ability to assess claims about treatment effects: the development of the ‘Claim Evaluation Tools’ (Manuscript). 2016.

38. Nedelsky L. Absolute grading standards for objective tests. Educ Psychol Meas. 1954;14(1):3–19.

39. Angoff WH. Scales, norms, and equivalent scores. In R. L. Thorndike (Ed.), Educational Measurement. Washington, DC: American Council on Education; 1971. p. 508–600.

40. Laursen JM. EpData Data entry, data management and basic statistical analysis system. Odense Denmark: EpData Association; 2000–2008.

41. Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med. 1992;116(1):78–84.

42. Donner A. Sample size requirements for stratified cluster randomized designs. Stat Med. 1992;11:743–50.

43. The Pan African Clinical Trial Registry, accessible from: www.pactr.org.

Submit your next manuscript to BioMed Central and we will help you at every step:

• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit